217 related articles for article (PubMed ID: 7855218)
41. Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex.
Dereń-Wesołek A; Maj J
Pol J Pharmacol; 1993; 45(5-6):467-80. PubMed ID: 7912135
[TBL] [Abstract][Full Text] [Related]
42. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.
Trullas R; Skolnick P
Eur J Pharmacol; 1990 Aug; 185(1):1-10. PubMed ID: 2171955
[TBL] [Abstract][Full Text] [Related]
43. Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonist--I. Pharmacological characterization in vitro.
Urwyler S; Laurie D; Lowe DA; Meier CL; Müller W
Neuropharmacology; 1996 Jun; 35(6):643-54. PubMed ID: 8887974
[TBL] [Abstract][Full Text] [Related]
44. Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine.
Ito K; Abekawa T; Koyama T
Psychopharmacology (Berl); 2006 Jul; 186(4):525-33. PubMed ID: 16758239
[TBL] [Abstract][Full Text] [Related]
45. Behavioral sensitization to ethanol does not result in cross-sensitization to NMDA receptor antagonists.
Meyer PJ; Phillips TJ
Psychopharmacology (Berl); 2007 Nov; 195(1):103-15. PubMed ID: 17653696
[TBL] [Abstract][Full Text] [Related]
46. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens.
Marcus MM; Mathé JM; Nomikos GG; Svensson TH
Neuropharmacology; 2001 Mar; 40(4):482-90. PubMed ID: 11249957
[TBL] [Abstract][Full Text] [Related]
47. N-methyl-D-aspartate antagonist activity of alpha- and beta-sulfallorphans.
Shukla VK; Lemaire S
J Pharmacol Exp Ther; 1997 Jan; 280(1):357-65. PubMed ID: 8996216
[TBL] [Abstract][Full Text] [Related]
48. Characterization of the discriminative stimulus effects of N-methyl- D-aspartate ligands under different ethanol training conditions in the cynomolgus monkey ( Macaca fascicularis).
Vivian JA; Waters CA; Szeliga KT; Jordan K; Grant KA
Psychopharmacology (Berl); 2002 Jul; 162(3):273-81. PubMed ID: 12122485
[TBL] [Abstract][Full Text] [Related]
49. Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors.
Kretschmer BD
J Neurochem; 1999 Aug; 73(2):839-48. PubMed ID: 10428083
[TBL] [Abstract][Full Text] [Related]
50. Anticonvulsant effects of eliprodil alone or combined with the glycineB receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats.
Wlaź P; Ebert U; Löscher W
Neuropharmacology; 1999 Feb; 38(2):243-51. PubMed ID: 10218865
[TBL] [Abstract][Full Text] [Related]
51. MK-801 and phencyclidine act at phencyclidine sites that are not linked to N-methyl-D-aspartate activity to inhibit behavioral sensitization to kainate.
Sun X; Larson AA
Neuroscience; 1993 Jun; 54(3):773-9. PubMed ID: 8101361
[TBL] [Abstract][Full Text] [Related]
52. Modulation of the PCP/NMDA receptor complex and sigma binding sites by psychostimulants.
Itzhak Y
Neurotoxicol Teratol; 1994; 16(4):363-8. PubMed ID: 7526145
[TBL] [Abstract][Full Text] [Related]
53. A rapid method for evaluating the behavioral effects of phencyclidine-like dissociative anesthetics in mice.
Evoniuk GE; Hertzman RP; Skolnick P
Psychopharmacology (Berl); 1991; 105(1):125-8. PubMed ID: 1660607
[TBL] [Abstract][Full Text] [Related]
54. The utility of excitatory amino acid (EAA) antagonists as analgesic agents. II. Assessment of the antinociceptive activity of combinations of competitive and non-competitive NMDA antagonists with agents acting at allosteric-glycine and polyamine receptor sites.
Coderre TJ; Van Empel I
Pain; 1994 Dec; 59(3):353-359. PubMed ID: 7708409
[TBL] [Abstract][Full Text] [Related]
55. Characterization of the non-competitive antagonist binding site of the NMDA receptor in dark Agouti rats.
Sun W; Wessinger WD
Life Sci; 2004 Aug; 75(12):1405-15. PubMed ID: 15240177
[TBL] [Abstract][Full Text] [Related]
56. The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex.
Tricklebank MD; Bristow LJ; Hutson PH; Leeson PD; Rowley M; Saywell K; Singh L; Tattersall FD; Thorn L; Williams BJ
Br J Pharmacol; 1994 Nov; 113(3):729-36. PubMed ID: 7858861
[TBL] [Abstract][Full Text] [Related]
57. Effects of antagonists at the NMDA receptor complex in two models of anxiety.
Plaznik A; Palejko W; Nazar M; Jessa M
Eur Neuropsychopharmacol; 1994 Dec; 4(4):503-12. PubMed ID: 7894261
[TBL] [Abstract][Full Text] [Related]
58. A competitive antagonist of NMDA receptors CGP 40116 attenuates experimental symptoms of schizophrenia evoked by MK-801.
Zajaczkowski W; Czyrak A; Wedzony K
Pol J Pharmacol; 2003; 55(5):703-11. PubMed ID: 14704466
[TBL] [Abstract][Full Text] [Related]
59. Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex.
Skolnick P; Miller R; Young A; Boje K; Trullas R
Psychopharmacology (Berl); 1992; 107(4):489-96. PubMed ID: 1534910
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological specificity of the discriminative stimulus properties of 2-amino-4,5-(1,2-cyclohexyl)-7-phosphono-heptanoic acid (NPC 12626), a competitive N-methyl-D-aspartate receptor antagonist.
Bobelis DJ; Balster RL
J Pharmacol Exp Ther; 1993 Feb; 264(2):845-53. PubMed ID: 8437128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
